In another study, daratumumab plus lenalidomide and dexamethasone (D-Rd) downregulated CD38 expression in multiple myeloma (MM) patients compared to Rd, especially in NK cells, B cells, basophils, monocytes, and CD4+ T cells, with no significant change in CD8+ T cells. The gene discussed is CD38; the disease is plasma cell myeloma.